Annual report
Home
Sitemap
Contact
Search
Highlights
Facts and Figures
New product registrations in 2009
Countries in our marketing partner network
Key Products
Dermatology
Oral health
Vision and Strategy
Chairman's Statement
Global Operations
Business Review
Business Review - Operational
Business Review - Financial
Global Partnership
Pipeline
Management and Governance
Board of Directors
Senior Management
Directors' Report
Statement of Directors' Responsibilities
Corporate Governance Report
Directors' Remuneration Report
Auditors' Report
Financial Statements
Consolidated Income Statement
Balance Sheet
Statement of Changes in Shareholders' Equity
Cash Flow Statements
Notes to the Financial Statements
Corporate Advisors
Sinclair
Consolidated Income Statement
Balance Sheet
Statement of Changes in Shareholders' Equity
Cash Flow Statements
Notes to the Financial Statements
1. General information
2. Accounting Policies
3. Financial risk management
4. Segmental information
5. Exceptional operating items
6. Expenses by nature
7. Employees and Directors
8. Finance Income and costs
9. Taxation on loss on ordinary activities
10. Loss for the financial year
11. Loss per share
12. Goodwill
13. Intangible asssets
14. Property, plant and equipment
15. Investments
16. Deferred tax asset
17. Inventories
18. Trade and other receivables
19. Trade and other payables
20. Borrowings
21. Provisions
22. Financial instruments
23. Called-up share capital
24. Share premium
25. Options and warrants over shares of Sinclair Pharma plc
26. Share based payments
27. Other Reserves
28. Cash flows from operating activities
29. Operating lease commitments
30. Capital commitments
31. Related party transactions
32. Post balance sheet events
Print this page
Add to print basket
View print basket
(0)
Email this page
Home
>
Financial Statements
>
Notes to the Financial Statements
> 30. Capital commitments
30 Capital commitments
The Group and Company had no capital commitments at 30 June 2009 (2008: £nil).